首页> 外文OA文献 >PND17 Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies

【2h】

PND17 Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies

机译：PND17 Glatiramer醋酸盐40毫克/毫升，一周三次，用于治疗复发性多发性硬化症：不经常注射的治疗方案的潜在成本收益，可最大程度地减少向新引入的一线和二线疾病修正疗法的转换

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Garcia Bujalance L; Kelly M; Blackney M; Zeidman R; Skroumpelos A; Bijedic A; Sánchez-de la Rosa R; Plich A;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study [J] . Zivadinov Robert, Bergsland Niels, Hagemeier Jesper, Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology . 2018,第期

机译：从Glatiramer乙酸盐/每天切换到Glatiramer醋酸盐的效果每周进行40毫克的灰色和白质病理到复发多发性硬化的受试者：纵向DTI研究
2. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study [J] . Khan Omar, Rieckmann Peter, Boyko Alexey, Multiple sclerosis: clinical and laboratory research . 2017,第6期

机译：三次每周给药方案的疗效和安全性醋酸三次醋酸多发性硬化症患者的疗效和安全性：Glatamer乙酸盐低频管理的3年结果开放标签扩展研究
3. Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study. [J] . Kolodny S., Khan O., Rieckmann P., Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：醋酸格拉替雷在复发-缓解型多发性硬化症患者中每周三次给药方案的疗效和安全性：醋酸格拉替雷低频管理（GALA）开放标签扩展研究的3年结果。
4. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis [O] . Christine Bell, James Anderson, Tanmoy Ganguly, -1

机译：Glatopa®（醋酸格拉默）的开发：首个获得FDA批准的多发性硬化症复发形式的通用疾病改良疗法
5. PND19 The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies [O] . Blackney M., Kelly M., Zeidman R., 2014

机译：PND19将复发缓解型多发性硬化症患者从醋酸格拉替雷转换为新批准的疾病修正疗法的成本负担

PND17 Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies

著录项

引文网络

相似文献

相关主题

期刊订阅